Cancer testis antigens (CTA) constitutes a large group of tumor‐associated antigens with expression restricted to male germ cells in the testis. CTAs are not expressed in adult somatic tissues or during immunological development. In cancer, this gene control is lost, resulting in CTA expression in various types of tumors.
This tumor‐restricted pattern of expression, together with their robust in vivo immunogenicity, has identified CTAs as ideal targets for immunotherapeutic approaches, and encouraged the development of CTA‐based anti-cancer vaccines.
Important CT antigens in cancer therapy include MAGE-A1, MAGE-A3, MAGE-A4, NY-ESO-1, PRAME, CT83 and SSX2.
The Ludwig Institute for Cancer Research (LICR) maintains a database for cancer testis antigens.
The expression of cancer testis antigens in malignancies is heterogeneous and often relates to tumor progression. CTAs have been identified in melanoma, liver cancer, lung cancer, bladder cancer, and pediatric cancers such as neuroblastoma.
CTA-specific cytotoxic T-cell responses have been reported in patients with a variety of the above mentioned tumors. These responses can be determined by Tetramer assays for CD8+ CTA-specific T cells in peripheral blood and in tumor-infiltrating lymphocytes (TILs) from tumor biopsies.
Tetramer reagents from Tetramer Store include Tetramers for detection of T cells specific for antigens derived from MAGE-A1, MAGE-A3 MAGE-A4, NY-ESO-1 and PRAME presented in context of MHC molecules HLA-A02:01, HLA-A24:02 and HLA-B07:02.
CTA relevant Tetramers >> Go to shop
Cat. No. | HLA type | Pep. Seq. | Antigen |
HA02-002 | HLA-A*02:01 | SLLMWITQV | NY-ESO-1 157-165 |
HA02-003 | HLA-A*02:01 | SLLMWITQC | NY-ESO-1 157-165 (9C) |
HA02-007 | HLA-A*02:01 | KVLEYVIKV | MAGEA1 278-286 |
HA02-004 | HLA-A*02:01 | KVAELVHFL | MAGEA3 112-120 |
HA02-068 | HLA-A*02:01 | GVYDGREHTV | MAGE-A4 230-239 |
HA02-138 | HLA-A*02:01 | VLDGLDVLL | PRAME 100-108 |
Controls
Cat. No. | HLA type | Pep. Seq. | Antigen |
HA02-024 | HLA-A*02:01 | AVIAPVHAV | None natural found |
HA02-025 | HLA-A*02:01 | GVAGDVSAV | None natural found |
HA02-014 | HLA-A*02:01 | SLYNTVATL | HIV-1 gag p17 76-84 |
Other relevant cancer related Tetramers >> Go to shop
Cat. No. | HLA type | Pep. Seq. | Antigen |
HA02-005 | HLA-A*02:01 | YMDGTMSQV | Tyrosinase 369-377 (371D) |
HA02-006 | HLA-A*02:01 | IMDQVPFSV | gp100 (pmel17) 209-217 |
HA02-019 | HLA-A*02:01 | ITDQVPFSV | gp100 (pmel) 209-217 |
HA02-001 | HLA-A*02:01 | ELAGIGILTV | MelanA / MART 26-35 |
HA24-001 | HLA-A*24:02 | AFLPWHRLF | Tyrosinase 188-196 |
HA24-022 | HLA-A*24:02 | VYFFLPDHL | gp100-intron 4 (170-178) |
HB07-006 | HLA-B*07:02 | LPWHRLFLL | Tyrosinase 208-216 |
Application of CTA-specific Tetramers
Tetramers are useful in Tetramer protocols for detection, enumeration and isolation of antigen-specific CD8+ T cells in a variety of applications e.g. during cancer vaccine – and immunotherapeutic development. CTA-specific Tetramers can be used for profiling of CTA-specific T-cell responses to vaccines by monitoring of pre-existing and induced immunity.
General information about MHC Tetramers from Tetramer Shop
Tetramer Store supply MHC Tetramers in various test sizes and the colors PE, BV421, BUV395, APC-Cy™7, APC, BV510, BV480, PE-Cy™5, PE-CF594, PE-Cy™7, PerCP-Cy™5.5, PerCP, FITC, BV605 and BUV737. For other colors, please enquire.
Tetramer Store also supply Empty Loadable Tetramers for instant loading of peptide antigens essentially representing DIY Tetramers.